AYUSHMAN BHARAT · KASDAP HEALTHCARE
Ayushman Bharat is India's most ambitious health financing initiative. Understanding how this programme is reshaping pharmaceutical demand and healthcare access is essential for every stakeholder in India's health ecosystem.
What Is Ayushman Bharat?
Ayushman Bharat — Pradhan Mantri Jan Arogya Yojana (PM-JAY) — is the world's largest publicly funded health insurance scheme, launched by the Government of India in 2018. It provides health coverage of up to Rs. 5 lakh per family per year for secondary and tertiary hospitalisation, targeting the bottom 40% of India's population — approximately 500 million people from around 100 million vulnerable families.
The scheme covers over 1,500 medical packages including surgeries, medical treatments, and day-care procedures across 24 specialty areas. Empanelled public and private hospitals across India can provide cashless treatment to eligible beneficiaries, fundamentally changing how healthcare is accessed by India's most economically vulnerable populations.
Ayushman Bharat's Impact on Pharmaceutical Demand
By funding hospitalisation for conditions previously left untreated due to financial barriers, PM-JAY has significantly expanded the patient pool accessing formal medical treatment. This directly drives demand for pharmaceutical products used in hospital settings — injectables, surgical antibiotics, anaesthetic agents, cardiac medicines, and oncology supportive care.
Empanelled hospitals are required to provide all approved medicines to PM-JAY patients at no cost, sourced from their own pharmacy inventories. This creates significant incentive for hospital pharmacies to maintain comprehensive inventories from quality-assured, cost-competitive suppliers.
Health and Wellness Centres: Primary Care Transformation
The second pillar of Ayushman Bharat is the Health and Wellness Centre (HWC) programme, which transforms existing Sub-Centres and Primary Health Centres into comprehensive primary care facilities delivering an expanded package of services including screening and management of non-communicable diseases (NCDs), mental health care, oral health care, and ENT care.
HWCs are mandated to provide free medicines for 12 NCD categories including hypertension, diabetes, common cancers, and respiratory diseases. This significantly expands the rural medicine supply chain, creating demand for quality generic medicines at the primary care level across India's 150,000+ HWCs.
CGHS and ESIC: Other Government Health Programmes
Central Government Health Scheme (CGHS)
CGHS provides comprehensive healthcare to central government employees, pensioners, and their dependents through a network of wellness centres and empanelled hospitals across 75+ Indian cities. CGHS medicines are procured through rate contracts with approved suppliers, providing another significant institutional medicine supply channel.
Employees State Insurance Corporation (ESIC)
ESIC covers organised sector workers and their families, providing comprehensive medical care including medicines through its network of hospitals and dispensaries. With approximately 135 million beneficiaries, ESIC represents a major pharmaceutical procurement channel requiring quality-assured generic supply at competitive prices.
National Disease Control Programmes: Medicines at Scale
India's national disease programmes — the Revised National Tuberculosis Control Programme (now National TB Elimination Programme), the National Vector Borne Disease Control Programme (malaria, dengue, kala-azar), and the National AIDS Control Programme — collectively consume enormous quantities of pharmaceuticals. These programmes rely on quality-assured generic medicines at the scale required to treat millions of patients annually.
Universal Health Coverage: The Unfinished Journey
India has made significant progress toward Universal Health Coverage (UHC) through PM-JAY, HWCs, and national disease programmes. Yet significant gaps remain: out-of-pocket spending remains among the highest in the world as a proportion of total health spending; rural-urban healthcare quality gaps persist; and medicine availability at peripheral facilities remains inconsistent.
Closing these gaps requires sustained investment in healthcare infrastructure, pharmaceutical supply chain strengthening, and the deployment of quality-assured, affordable medicines across every level of the healthcare system — from tertiary hospitals in metropolitan centres to HWCs in remote tribal areas.
Kasdap Healthcare's Role in India's Healthcare Mission
Kasdap Healthcare's mission is aligned with India's Universal Health Coverage goals: delivering quality-assured, affordable pharmaceutical products to every segment of the healthcare system. Our pan-India distribution network, WHO-GMP certified product portfolio, and commitment to compliance make us a trusted partner for institutions, distributors, and healthcare providers serving India's growing and diversifying healthcare demand.
Join Kasdap's growing distribution network
